Phase 2b trial studies bepirovirsen for treatment of chronic hepatitis B infection
A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9–10% of patients with chronic HBV infection, according to a study published ...
Nov 14, 2022
0
27